Market closedNon-fractional
Cue Biopharma/CUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Ticker
CUE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
53
Website
www.cuebiopharma.com
Cue Biopharma Metrics
BasicAdvanced
$34M
Market cap
-
P/E ratio
-$1.06
EPS
1.99
Beta
-
Dividend rate
Price and volume
Market cap
$34M
Beta
1.99
Financial strength
Current ratio
2.469
Quick ratio
2.345
Long term debt to equity
19.385
Total debt to equity
43.265
Interest coverage (TTM)
-45.95%
Management effectiveness
Return on assets (TTM)
-47.26%
Return on equity (TTM)
-117.50%
Valuation
Price to revenue (TTM)
4.705
Price to book
1.13
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
-0.848
Growth
Revenue change (TTM)
1,525.00%
Earnings per share change (TTM)
-20.69%
3-year revenue growth (CAGR)
22.62%
3-year earnings per share growth (CAGR)
-10.81%
What the Analysts think about Cue Biopharma
Analyst Ratings
Majority rating from 5 analysts.
Cue Biopharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
-5.56%
Net income
-$12M
-8.21%
Profit margin
-723.52%
-2.81%
Cue Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.24
-$0.29
-$0.25
-
Expected
-$0.31
-$0.34
-$0.28
-$0.28
-$0.29
Surprise
-4.92%
-29.93%
4.32%
-11.35%
-
Cue Biopharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cue Biopharma stock?
Cue Biopharma (CUE) has a market cap of $34M as of July 27, 2024.
What is the P/E ratio for Cue Biopharma stock?
The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of July 27, 2024.
Does Cue Biopharma stock pay dividends?
No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cue Biopharma dividend payment date?
Cue Biopharma (CUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Cue Biopharma?
Cue Biopharma (CUE) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cue Biopharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.